Press release
February 17, 2015

GENOMICS | DIAGNOSTIC TESTS | GENETICS | R&D

Genomic Vision renews its Strategic Collaboration with Quest Diagnostics for three more years

- Rights granted to Genomic Vision to enter into further partnerships in the USA and to market new molecular diagnostic tests around the world
- A substantial increase in royalty rate from the sales of molecular combing tests

Bagneux (France) - Genomic Vision (FR0011799907 – GV / PEA-PME eligible), a molecular diagnostics company specialized in the development of diagnostic tests for genetic diseases and cancers based on molecular combing, today announces that it has signed an amendment to its contract with Quest Diagnostics to extend their strategic collaboration based on Genomic Vision's technology. The amendment extends the collaboration for three more years, until November 2018.

Under the terms of the amendment, Quest Diagnostics retains exclusive rights to develop, validate and market tests based on molecular combing in the fields of breast and ovarian cancer, such as BRCA gene mutation testing, hereditary colon cancer (Lynch syndrome), spinal muscular atrophy (SMA) and facioscapulohumeral muscular distrophy (FSHD) in the United States, India and Mexico.

Genomic Vision will continue to retain exclusive rights to market its tests in Europe, the Middle East and Africa, per the original agreement with Quest. Quest Diagnostics, an equity owner in Genomic Vision, has granted Genomic Vision rights to seek to develop new diagnostic tests in partnership with other providers of diagnostic services or medical centers in the United States and to market them all over the world. Genomic Vision will be able to accelerate the number of diagnostic tests offered utilizing its technology by working with leaders in many fields worldwide.

Quest will receive credits against milestone payments earned by Genomic Vision in consideration for the rights granted. The royalty rate paid to Genomic Vision by Quest Diagnostics for the provision of testing services based on laboratory-developed molecular combing tests will increase significantly. Additional terms were not disclosed.

The extension follows an announcement by Genomic Vision in January 2015 that it had delivered a high-throughput molecular-combing genome analyzer to the Quest Diagnostics Nichols Institute, an advanced genomics and R&D laboratory center in San Juan Capistrano, Calif.

Charles (Buck) Strom, MD, PhD, Medical Director of Quest Diagnostics Nichols Institute, Quest Diagnostics, comments: *"We believe molecular combing is a potential break-through technology for analyzing and detecting gene variants missed by other techniques, making it a superb complement to our next generation sequencing offerings. We look forward to continuing to develop the clinical and commercial value of this technology with future genomic services."*

"This is a truly great opportunity for Genomic Vision, which will increase our value-creation potential in new indications with new diagnostics players in the United States. In the constantly evolving genetic testing market, healthcare providers and medical laboratories have technological choices, and we are proud that molecular combing is being considered by the world's leading diagnostic information services provider to advance its portfolio of services for detecting hereditary cancers and other genetic diseases," said **Aaron Bensimon, Genomic Vision's co-founder and President of the Management board**.

•••

ABOUT GENOMIC VISION

Founded in 2004, Genomic Vision is a molecular diagnostics company specialized in the development of diagnostic tests for genetic diseases and cancers based on molecular combing. Using this innovative technology that allows the direct visualization of individual DNA molecules, Genomic Vision detects quantitative and qualitative variations in the genome that are at the origin of numerous serious pathologies. The Company is developing a solid portfolio of tests that notably target breast cancer and cancer of the colon. Since 2013, the Company has marketed the CombHeliX FSHD test for identifying a myopathy that is difficult to detect, Facio-scapulo-humeral dystrophy (FSHD), in the United States thanks to a strategic alliance with Quest Diagnostics, the American leader in diagnostic laboratory tests, and in France. Genomic Vision has been listed on Compartment C of Euronext Paris since April 2014.

ABOUT MOLECULAR COMBING

DNA molecular combing technology considerably improves the structural and functional analysis of DNA molecules. DNA fibers are stretched out on glass slides, as if "combed", and uniformly aligned over the whole surface. It is then possible to identify genetic anomalies by locating genes or specific sequences in a patient's genome using genetic markers, an approach developed by Genomic Vision and patented under the name Genomic Morse Code. This exploration of the entire genome at high resolution via a simple analysis enables the direct visualization of genetic anomalies that are undetectable by other technologies.

For further information, please go to www.genomicvision.com

CONTACTS

Genomic Vision
Aaron Bensimon
Co-founder, Chairman & CEO
Tel.: +33 1 49 08 07 50
investisseurs@genomicvision.com

NewCap
Investor Relations / Strategic Communications
Dušan Orešanský / Emmanuel Huynh
Tel.: +33 1 44 71 94 92
gv@newcap.fr

GV LISTED EURONEXT

ELIGIBLE PEA PME

DISCLAIMER

This press release contains certain forward-looking statements concerning Genomic Vision and its business. Such forward-looking statements are based on assumptions that Genomic Vision considers to be reasonable. However, there can be no assurance that such forward-looking statements will be verified, which statements are subject to numerous risks, including the risks set forth in the prospectus on which the French Financial Market Authority (AMF) granted its visa n° 14-087 on March 19, 2014 and to the development of economic conditions, financial markets and the markets in which Genomic Vision operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Genomic Vision or not currently considered material by Genomic Vision. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Genomic Vision to be materially different from such forward-looking statements.

This press release and the information contained herein do not constitute and should not be construed as an offer or an invitation to sell or subscribe, or the solicitation of any order or invitation to purchase or subscribe for GENOMIC VISION shares in any country. The distribution of this press release in certain countries may be a breach of applicable laws. The persons in possession of this press release must inquire about any local restrictions and comply with these restrictions.